Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  ESSILOR INTL.    EI   FR0000121667

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

ESSILOR INTL. : Essilor Continues to Expand in the United States

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/31/2013 | 06:35am CEST

Regulatory News:

Essilor (Paris:EI) is continuing to strengthen its positions in the United States, the world's leading market for ophthalmic lenses, with the acquisition of a lens manufacturer and a new prescription laboratory.

The Company has announced the acquisition of an 80% share in X-Cel Optical, a manufacturer of ophthalmic lenses based in Minnesota (US). Leveraging its widely recognized, high performance technical expertise, X-Cel Optical offers a wide range of niche products, the vast majority of which are bi- and tri-focal, stock and variable-tint lenses. The line-ups are produced in various materials, including Trivex?. With a refraction index of 1.53 and impact resistance comparable to that of polycarbonate, Trivex? is enjoying rapid sales growth.

X-Cel Optical produces just over two million lenses a year and generates full-year revenue of approximately $33 million.

The development of the X-Cel Optical product line, which fits very well with Essilor's, will be led by the Group's various distribution networks in the United States, comprising both proprietary and independent laboratories, and around the world. The X-Cel Optical offer may also be moved upmarket, using Essilor's leading-edge technologies, in particular the Crizal® range of surface coatings, as a lever.

In addition, the partnership will enable Essilor to optimize its sourcing strategy. Lastly, Essilor and X-Cel Optical may also share their engineering skills and capabilities to optimize their production processes.

Essilor is also continuing to deepen its local distribution network in the United States to capture the market's growth potential for value-added lenses. The Company has signed a partnership with Lenstech Optical, a prescription laboratory in Indiana that generates annual revenue of $6 million.

In the future, Essilor will activate the usual value-creation levers by providing Lenstech Optical with new technologies that will speed the distribution of its flagship brands, including Varilux® and Crizal®, in the partner's catchment area.

About Essilor

The world's leading ophthalmic optics company, Essilor designs, manufactures and markets a wide range of lenses to improve and protect eyesight. Its corporate mission is to enable everyone around the world to access lenses that meet his or her unique vision requirements. To support this mission, the Company allocates around ?150 million to research and development every year, in a commitment to continuously bring new, more effective products to market. Essilor's flagship brands are Varilux®, Crizal®, Definity®, Xperio®, Optifog? and Foster Grant®. It also develops and markets equipment, instruments and services for eyecare professionals.

Essilor reported consolidated revenue of ?4.2 billion in 2011 and employs around 48,700 people in some 100 countries. It operates 19 plants, a total of 390 prescription laboratories and edging facilities, as well as several research and development centers around the world.

For more information, please visit www.essilor.com.

The Essilor share trades on the NYSE Euronext Paris market and is included in the EuroStoxx 50 and CAC 40 indices. Codes and symbols: ISIN: FR0000121667; Reuters: ESSI.PA; Bloomberg: EI:FP.

Investor Relations and
Financial Communication
Véronique Gillet ? Sébastien Leroy ? Ariel Bauer
Phone: +33 (0)1 49 77 42 16
or
Media Relations
Maïlis Thiercelin
Phone: +33 (0)1 49 77 45 02


© Business Wire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ESSILOR INTL.
04/25 ESSILOR INTL : First-Quarter 2017 Report
04/25 ESSILOR - NEWS RELEASE : Revenue increases by 10% / Q1 in line with planned 2017..
04/25 ESSILOR - NEWS RELEASE : Revenue increases by 10% / Q1 in line with planned 2017..
04/11 Paris CAC index falls 0.18%
04/11 ESSILOR INTL : Invitation to the holders of the two series of bonds due 2021 and..
04/10 ESSILOR INTL : Publishes an information document relating to the issuance of ord..
04/07 ESSILOR INTL : Procedures for Requesting or Viewing Proxy Information for the Co..
04/07 ESSILOR : Procedures for Requesting or Viewing Proxy Information for the Combine..
04/07 ESSILOR INTL : publishes an information document relating to the issuance of ord..
04/01 ESSILOR INTL : Corpus Christi Caller-Times, Texas, David Sikes column
More news
Sector news : Glasses, Spectacles & Contact lenses
04/24DJWHAT'S NEWS : Business & Finance -- WSJ
04/24 Becton Dickinson to acquire Bard for $24 billion
04/23DJBECTON DICKINSON AND : to Acquire C.R. Bard for $24 Billion
04/19DJCardinal Swoops In, Strikes Deal -- WSJ
04/18DJCARDINAL HEALTH : $6.1 Billion Deal for Some Medtronic Operations Raises Debt Co..
More sector news : Glasses, Spectacles & Contact lenses
News from SeekingAlpha
04/25 Essilor International (ESLOF) Q1 2017 Results - Earnings Call Transcript
04/25 Essilor International SA reports Q1 results
03/10 LUXOTTICA : Positioned To Dominate The Eyewear Market For Years To Come
02/17 Essilor International SA ADR reports FY results
01/18 LUXOTTICA AND ESSILOR : Bullish On The Company, But Not On The Stock
Advertisement
Financials (€)
Sales 2017 7 759 M
EBIT 2017 1 393 M
Net income 2017 911 M
Debt 2017 1 701 M
Yield 2017 1,25%
P/E ratio 2017 28,37
P/E ratio 2018 25,73
EV / Sales 2017 3,56x
EV / Sales 2018 3,28x
Capitalization 25 960 M
More Financials
Chart ESSILOR INTL.
Duration : Period :
ESSILOR INTL. Technical Analysis Chart | EI | FR0000121667 | 4-Traders
Full-screen chart
Technical analysis trends ESSILOR INTL.
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 126 €
Spread / Average Target 6,3%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Hubert Sagnières Chairman & Chief Executive Officer
Laurent Vacherot President & Chief Operating Officer
Paul du Saillant Co-Chief Operating Officer
Jean Carrier-Guillomet Chief Operating Officer
Géraldine Picaud Chief Financial Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ESSILOR INTL.10.71%28 296
COOPER COMPANIES INC14.33%9 787
SHANGHAI CONANT OPTICS..--.--%1 421
MENICON CO LTD3.95%566
INTEROJO CO. LTD.--.--%378
TEARLAB CORP-53.64%13
More Results